7-benzyl-4-chloro-2-(2-(trifluoromethyl)benzyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine | 1309870-86-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 7-benzyl-4-chloro-2-(2-(trifluoromethyl)benzyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine
• CAS: 1309870-86-7
• 化学式: C₂₃H₂₁ClF₃N₃
• 分子量: 431.888
• InChiKey: FKAOFCBQYMAQOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.34
• 重原子数：
  30.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.02
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  7-benzyl-4-chloro-2-(2-(trifluoromethyl)benzyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine 在 palladium on carbon 、 氨 、 水 、 甲酸铵 、 锌 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 12.0h， 生成 2-[[2-(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine
  参考文献：
  名称：

  Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: Design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence

  摘要：

  New pyrimido[4,5-d]azepines 7 are disclosed as potent 5-HT2C receptor agonists. A preferred example, 7b had minimal activation at either the 5-HT2A or 5-HT2B receptors combined with robust efficacy in a preclinical canine model of stress urinary incontinence (SUI) and attractive pharmacokinetic and safety properties. Based on this profile, 7b (PF-3246799) was identified as a candidate for clinical development for the treatment of SUI. In addition, it proved to be critical to build an understanding of the translation between recombinant cell-based systems, native tissue preparations and in vivo preclinical models. This was a significant undertaking and proved to be crucial in compound selection. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.120
• 作为产物：
  描述：

  在 四乙基氯化铵 、 三氯氧磷 作用下， 以 丙腈 为溶剂， 反应 18.0h， 生成 7-benzyl-4-chloro-2-(2-(trifluoromethyl)benzyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine
  参考文献：
  名称：

  Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: Design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence

  摘要：

  New pyrimido[4,5-d]azepines 7 are disclosed as potent 5-HT2C receptor agonists. A preferred example, 7b had minimal activation at either the 5-HT2A or 5-HT2B receptors combined with robust efficacy in a preclinical canine model of stress urinary incontinence (SUI) and attractive pharmacokinetic and safety properties. Based on this profile, 7b (PF-3246799) was identified as a candidate for clinical development for the treatment of SUI. In addition, it proved to be critical to build an understanding of the translation between recombinant cell-based systems, native tissue preparations and in vivo preclinical models. This was a significant undertaking and proved to be crucial in compound selection. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.120